Monoclonal antibodies may play a frontline role in dealing with COVID-19 infections, according to Anthony S. Fauci, MD.
Much has been made of treatments for advanced coronavirus disease 2019 (COVID-19) infection, but early-stage treatments such as monoclonal antibodies (mAbs) and direct-acting antivirals (DAAs) are showing promise, said Anthony S. Fauci, MD, director of the National Institute of Allergy and Infection Diseases, in a recent town hall meeting.
Among mAbs, for instance, the infliximab biosimilar Remsima is undergoing testing in the CATALYST study for treatment of COVID-19 related inflammation. The Celltrion Healthcare drug has previously been employed for inflammatory conditions, which investigators believe makes it a promising candidate for treatment of COVID-19.
DAAs target specific virus proteins and disrupt viral replication and infection. Also showing promise, Fauci said, are convalescent plasma and hyperimmune globulin, therapies that involve antibody-laden blood taken from patients who have recovered from COVID-19. “There’s a lot of drugs and interventions that are actually being tested right now,” he said.
Although those are largely experimental, there is sound progress in treatment of late-stage disease, Fauci noted. Two drugs have been shown in placebo-controlled trials to have a beneficial effect in advanced disease. One is the antiviral remdesivir, which has significantly reduced time to recovery and hospital discharge, and the second is dexamethasone, an anti-inflammatory that has reduced the death rate in patients with COVID-19 not yet on ventilators but who need supplementary oxygen. These drugs are already recommended by guidelines-setting authorities for treatment of COVID-19, Fauci said.
A Poster Child
Against the global backdrop, the United States has at times been exemplary for how not to manage the spread of COVID-19, but Fauci said he and others are in regular, weekly consults hosted by the World Health Organization to share information and experience.
“We have scientific collaboration with colleagues in the European Union, Australia, Canada, and Mexico. We have clinical trial networks in South Africa, Brazil, Chile, and Peru. So, there’s an awful lot of international activity going on. You don’t hear very much about that…, but it’s going on rather intensively," he noted.
Based on the progress, should schools be opening in the United States? Fauci said it all depends.
“The genuine default condition should be to try as best as you can to open up the schools for the reasons that the American Academy of Pediatrics has articulated very well: the psychological health of children, sometimes dependent on nutrition for breakfasts and lunches, and the secondary, downstream ripple effects that are negative for the families that might have to interrupt work to take care of the kids,” he said.
That said, it’s necessary to maintain the health of parents, relatives, and teachers as well as children, and “we live in a big country that has different levels of infection in different regions, states, cities, counties.” Some areas have less than 5% test-positivity for COVID-19 infection, and so you can open schools there “with relatively little impunity,” he said.
In areas with 5% to 10% test-positivity, there are CDC guidelines to help determine how to open schools and still protect school children and prevent the spread of infection. For areas in the “red zone” with greater than 10% test-positivity, “you really better think twice before you do that, because what might happen is you go in, people get infected, and—Boom!—they close them down,” he said.
“The bottom line is we live in a big country and we can’t take a unidimensional approach. Taking the country as a whole won’t work. We’re so heterogeneous,” Fauci said.
In other pandemic clinical developments, biosimilar interferon beta-1a (IFN-β-1a, ReciGen) has shown effectiveness in helping to reduce symptoms and achieve virological clearance in patients with COVID-19.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.